US equities
|
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
NextCure, Inc. - Common Stock
(NQ:
NXTC
)
6.240
-0.640 (-9.30%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about NextCure, Inc. - Common Stock
< Previous
1
2
3
Next >
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
August 06, 2026
From
NextCure
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether VEEE, NXTC, TCBK, FHB are Obtaining Fair Deals for their Shareholders
July 23, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders
July 21, 2026
From
Ademi LLP
Via
GlobeNewswire
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders
July 14, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Kartoon Studios (NYSE: TOON) Enters Catalyst-Rich Growth Phase
July 14, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Intellectual Property
Power Moves: NXTC, TOON, SHPH, COCH Entry Points Ignite on Major Catalysts
July 14, 2026
Via
AB Newswire
Topics
Artificial Intelligence
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders
July 14, 2026
From
Halper Sadeh LLC
Via
Business Wire
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
July 14, 2026
From
NextCure
Via
GlobeNewswire
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
June 04, 2026
From
NextCure
Via
GlobeNewswire
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
June 01, 2026
From
NextCure
Via
GlobeNewswire
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
May 07, 2026
From
NextCure
Via
GlobeNewswire
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
May 04, 2026
From
NextCure
Via
GlobeNewswire
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
April 21, 2026
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026
From
NextCure
Via
GlobeNewswire
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
April 07, 2026
From
NextCure
Via
GlobeNewswire
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
March 31, 2026
The American Society for Clinical Oncology to be held in Chicago May 29 – June 2, 2026
From
NextCure
Via
GlobeNewswire
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
March 05, 2026
From
NextCure
Via
GlobeNewswire
NextCure Provides Business Update
January 23, 2026
From
NextCure
Via
GlobeNewswire
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
November 20, 2025
From
NextCure
Via
GlobeNewswire
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
November 17, 2025
From
NextCure
Via
GlobeNewswire
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
November 12, 2025
From
NextCure
Via
GlobeNewswire
NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
November 05, 2025
From
NextCure
Via
GlobeNewswire
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
October 16, 2025
From
NextCure
Via
GlobeNewswire
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 04, 2025
From
NextCure
Via
GlobeNewswire
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
August 07, 2025
From
NextCure
Via
GlobeNewswire
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
July 24, 2025
From
NextCure
Via
GlobeNewswire
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
June 16, 2025
From
NextCure
Via
GlobeNewswire
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
May 29, 2025
From
NextCure
Via
GlobeNewswire
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
May 01, 2025
From
NextCure
Via
GlobeNewswire
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
April 04, 2025
From
NextCure
Via
GlobeNewswire
NextCure Provides Business Update and Reports Full Year 2024 Financial Results
March 06, 2025
From
NextCure
Via
GlobeNewswire
< Previous
1
2
3
Next >
